Matinas BioPharma Holdings, Inc. (MTNB)
0.1842
0.00 (0.00%)
USD |
NYAM |
Sep 09, 10:55
Matinas BioPharma Holdings Enterprise Value : 0.3609M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 0.3609M |
| September 04, 2026 | 0.3609M |
| September 03, 2026 | 0.3545M |
| September 02, 2026 | 0.3866M |
| September 01, 2026 | 0.4615M |
| August 31, 2026 | 0.4615M |
| August 28, 2026 | 0.4762M |
| August 27, 2026 | 0.4762M |
| August 26, 2026 | 0.4532M |
| August 25, 2026 | 0.4589M |
| August 24, 2026 | 0.4538M |
| August 21, 2026 | 0.4686M |
| August 20, 2026 | 0.3641M |
| August 19, 2026 | 0.7389M |
| August 18, 2026 | 0.4999M |
| August 17, 2026 | 0.6185M |
| August 14, 2026 | 0.6941M |
| August 13, 2026 | 0.6876M |
| August 12, 2026 | 0.7325M |
| August 11, 2026 | 0.8734M |
| August 10, 2026 | 0.9183M |
| August 07, 2026 | 1.008M |
| August 06, 2026 | 0.9144M |
| August 05, 2026 | 0.9567M |
| August 04, 2026 | 1.056M |
| Date | Value |
|---|---|
| August 03, 2026 | 1.127M |
| July 31, 2026 | 1.077M |
| July 30, 2026 | 1.228M |
| July 29, 2026 | 1.103M |
| July 28, 2026 | 1.072M |
| July 27, 2026 | 1.322M |
| July 24, 2026 | 0.7415M |
| July 23, 2026 | 0.7914M |
| July 22, 2026 | 0.9067M |
| July 21, 2026 | 0.9913M |
| July 20, 2026 | 1.211M |
| July 17, 2026 | 1.396M |
| July 16, 2026 | 1.479M |
| July 15, 2026 | 1.378M |
| July 14, 2026 | 1.436M |
| July 13, 2026 | 2.27M |
| July 10, 2026 | 4.034M |
| July 09, 2026 | 3.212M |
| July 08, 2026 | 3.141M |
| July 07, 2026 | 3.173M |
| July 06, 2026 | 3.218M |
| July 02, 2026 | 3.254M |
| July 01, 2026 | 3.237M |
| June 30, 2026 | 3.116M |
| June 29, 2026 | 2.995M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.326M |
| Total Expenses (Quarterly) | 1.326M |
| EPS Diluted (Quarterly) | -0.207 |
| Earnings Yield | -652.0% |
| Normalized Earnings Yield | -673.72 |